Jeffrey Allen Glenn

US Patent:

6627610, Sep 30, 2003

Filed:

Oct 13, 2000

Appl. No.:

09/687267

Inventors:

Jeffrey Glenn - Palo Alto CA 94304

International Classification:

A61K 3800

US Classification:

514 18, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17

Abstract:

Viral morphogenesis, production, release or uncoating can be inhibited by effecting inhibition of prenylation of, or inhibition of post-prenylation reactions of, at least one viral protein. The use of inhibitors of prenylation, and post-prenylation reactions, for example, inhibitors of the mevalonate and prenyl group synthesis pathways, inhibitors of prenyl group transferases and mimics of the prenylation target CXXX box are disclosed.

US Patent:

7326536, Feb 5, 2008

Filed:

May 3, 2002

Appl. No.:

10/481261

Inventors:

Jeffrey S. Glenn - Palo Alto CA, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US

Assignee:

Eli Lilly and Company - Indianapolis IN
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12Q 1/00
C12Q 1/66
C12Q 1/70
G01N 33/53
A61K 38/00
C07K 4/00
C07K 14/08

US Classification:

435 71, 435 4, 435 5, 435 72, 435 79, 435 8, 514 2, 530300, 530350

Abstract:

An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.

US Patent:

7582428, Sep 1, 2009

Filed:

Aug 18, 2004

Appl. No.:

10/528377

Inventors:

Jeffrey S. Glenn - Palo Alto CA, US
Shirit Einav - Stanford CA, US
Menashe Elazar - Palo Alto CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12Q 1/68
C12Q 1/00

US Classification:

435 6, 435 4, 435 5

Abstract:

The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e. g. , hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e. g. , an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e. g. , which is impaired in NTP binding).

US Patent:

7655419, Feb 2, 2010

Filed:

Aug 24, 2007

Appl. No.:

11/844993

Inventors:

Jeffrey Glenn - Palo Alto CA, US
Ella Sklan - Stanford CA, US
Kirk A. Staschke - Indianapolis IN, US
Tina Myers Oakes - Indianapolis IN, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Eli Lily and Company - Indianapolis IN

International Classification:

G01N 33/53
A61K 39/29

US Classification:

435 71, 4242281

Abstract:

The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods.

US Patent:

8093353, Jan 10, 2012

Filed:

Sep 4, 2007

Appl. No.:

11/899393

Inventors:

Jeffrey S. Glenn - Palo Alto CA, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 5/00

US Classification:

530300, 4242181

Abstract:

An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.

US Patent:

8211712, Jul 3, 2012

Filed:

Mar 29, 2006

Appl. No.:

11/887669

Inventors:

Nam-Joon Cho - Stanford CA, US
Curtis W. Frank - Cupertino CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Kwang Ho Cheong - Giheung-Gu, KR

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

G01N 33/543

US Classification:

436518

Abstract:

The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including, but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinsitol, cardiolipin, cholesterol, and sphingomyelin.

US Patent:

20030009775, Jan 9, 2003

Filed:

May 28, 2002

Appl. No.:

10/157099

Inventors:

Jeffrey Glenn - Palo Alto CA, US

International Classification:

A01K067/027

US Classification:

800/009000, 800/014000, 800/018000

Abstract:

A rodent model for HCV infection is obtained by introducing into rodents which harbor a liver-specific defect an expression system which comprises an HCV replicon or a reverse transcript thereof and at least a nucleotide sequence encoding a rescue protein which remedies the defect.

US Patent:

20030181355, Sep 25, 2003

Filed:

Dec 11, 2002

Appl. No.:

10/317644

Inventors:

Jeffrey Glenn - Palo Alto CA, US

International Classification:

A61K031/00
A61K038/06
A01N061/00
A01N037/18
A61K038/00

US Classification:

514/002000, 514/001000, 514/017000

Abstract:

The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein.